Tagged: cancer-therapy
3 results
Alpha-9 Oncology
Alpha-9 Oncology is a clinical-stage radiopharmaceutical company engineering bespoke, tumor-targeting molecules that deliver alpha- and beta-emitting isotopes directly to cancer cells while sparing healthy tissue. Spun out of the University of British Columbia and BC Cancer in 2019 and now headquartered in Boston with research operations in Vancouver, the company iteratively optimizes each part of a radiopharmaceutical - binder, linker, chelator and radioisotope - to build a pipeline of paired imaging and therapy candidates. Backed by $258M in total funding, including a $175M Series C in 2024, Alpha-9 aims to expand precision radiotherapy across validated oncology targets.
Edgewood Oncology
Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a first-in-class oral small-molecule multi-kinase inhibitor that co-targets casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7/CDK9) - three master regulators of cancer cell survival and transcription. Founded by veteran biotech executive David N. Cook and emerging from stealth in March 2024 with $20M in Series A financing from Alta Partners, the company is advancing BTX-A51 through Phase 2a trials in relapsed/refractory acute myeloid leukemia and genetically-defined (GATA3-mutant) ER+/HER2- metastatic breast cancer.
Andre Esteva
Andre Esteva, PhD, is the co-founder and CEO of ArteraAI, a medical AI company whose test for personalizing prostate cancer therapy is included in NCCN clinical guidelines, reimbursed by Medicare, and deployed internationally. A Stanford-trained AI scientist whose Nature cover paper first demonstrated that AI could match dermatologists at diagnosing skin cancer, Esteva has co-founded four companies with a combined market cap of $2.2B. Named to TIME100 Health 2025 and Modern Healthcare's 40 Under 40 for 2025, he leads a company that raised $175M total and was named a TIME 2024 Best Invention.